Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Guggenheim Adjusts Johnson & Johnson's Price Target to $156 From $160, Maintains Neutral Rating
Merck & Co. Poised for Growth: Strong Q2 Performance and Promising Pipeline Fuel Buy Rating
Buy Rating on UnitedHealth Group: Proactive Management and Strong Growth Outlook
Analysts' Opinions Are Mixed on These Healthcare Stocks: Elevance Health (ELV), CVS Health (CVS) and Abbott Laboratories (ABT)
Buy Rating Affirmed for Johnson & Johnson on Strong Growth and Strategic Acquisitions
Johnson & Johnson Analyst Ratings
AbbVie Analyst Ratings
BMO Capital Adjusts Price Target on Merck to $150 From $148
Morgan Stanley Keeps Their Hold Rating on Abbott Laboratories (ABT)
HSBC Adjusts Price Target on Johnson & Johnson to $174 From $170, Maintains Buy Rating
Jefferies Adjusts Price Target on Amgen to $380 From $375
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating
Nephron Adjusts Price Target on Abbott Laboratories to $110 From $115
Deutsche Bank Raises Price Target on UnitedHealth Group to $632 From $562, Keeps Buy Rating
Maintained Buy Rating for Abbott Laboratories on Strong Financials and Growth Prospects
Buy Rating Affirmed on Abbott Laboratories Amid Strong Q2 Results and Raised 2024 Guidance
UnitedHealth Group Analyst Ratings
UBS Adjusts UnitedHealth Group Price Target to $680 From $640, Maintains Buy Rating
RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target